Participated · Seed · May 2026

Rosarium Health provides a platform that coordinates the full lifecycle of home-based interventions, including in-home assessments by occupational and physical therapists, home modification recommendations, and contractor execution such as ramps and stair lifts. The company also automates documentation, prior authorization and claims submission to streamline payments and reimbursement. Rosarium operates a network of more than 800 clinicians and 3,000 contractors across 34 states and is in-network for 1.2 million Medicare and Medicaid lives, with plans to reach 4 million by year end. Financially, the company has raised $9 million to date, including a $6 million seed round led by Kalos Ventures. Rosarium plans to use recent funding to expand partnerships with Managed Medicaid and Medicare Advantage plans, particularly in California and the Northeast, and to scale its network and platform technology. The company’s stated goal is to make the home a reliable, large-scale site of care that reduces costs and improves outcomes for aging and underserved populations.

Participated · Seed · Mar 2026

Burst, formerly known as Float, offers a post-purchase healthcare payments platform designed for retailers and direct-to-consumer wellness brands. The software keeps merchants’ existing payment stacks intact while automatically identifying Health Savings Account (HSA) and Flexible Spending Account (FSA)–eligible items once a transaction is completed. After purchase, Burst notifies shoppers of potential savings and files reimbursement claims directly with their plan administrators, streamlining an otherwise manual process. This approach helps merchants access a larger share of the billions of dollars sitting in consumer HSA/FSA balances. Led by CEO Anthony Rangel, the New York City company plans to use new capital to accelerate product development and expand partnerships with retailers, e-commerce brands, and plan administrators. To date, Burst has raised a total of $3 million, indicating early but growing investor confidence in its model.

Led · Seed · Nov 2025

No Barrier is a San Francisco–based health-tech company building an AI-driven, real-time language interpretation platform for healthcare providers. The software embeds into existing electronic health record (EHR) systems with HIPAA-grade security, giving clinicians instant access to interpretation services for limited-English-proficiency (LEP) patients. Its solution is live in more than 100 healthcare sites across 12 U.S. states, covering hospitals and specialties such as mental health, reproductive care, and pediatrics. By eliminating wait times for translators and preserving patient privacy, the product aims to improve clinical outcomes and operational efficiency. The company generates revenue by selling its platform to health systems and individual providers, though specific revenue figures were not disclosed. With fresh capital, management plans to accelerate product development and broaden commercial deployment. Future initiatives include deeper EHR workflow integrations and expansion to additional specialties and geographies.

Led · Series A · Oct 2025

Founded in 2021, Pear Suite offers an AI-enabled software platform and wrap-around services that equip community health workers (CHWs), community-based organizations, and health plans with tools for care coordination, reimbursement, and data insights. The product lets CHWs use their lived experience to close care gaps and address social determinants of health while unlocking sustainable Medicaid and Medicare payments. Beyond software, Pear Suite is building a national provider network that already connects more than 300 provider organizations with over 25 health plans. The company has empowered 2,500+ CHWs, promotores, doulas, and other frontline workers to deliver trust-based interventions. With its new funding, management plans to increase the size of this provider network tenfold, deepen Medicaid relationships, and expand aggressively into Medicare contracts. The ultimate goal is to cement CHWs as a foundational part of U.S. healthcare by supplying the contracting, clinical, and claims infrastructure they need to thrive. While the company has not disclosed revenue figures, it recently strengthened its balance sheet with a $7.6 million Series A round.

Participated · Series A · Nov 2024

Synapticure is a patient- and caregiver-founded virtual care provider offering nationwide access to expert neurologists, cutting-edge treatments and clinical trials, wraparound care coordination, and behavioral health support for neurodegenerative diseases. Since its launch in 2022 the company has grown to serve several thousand patients across the United States as a specialty virtual care platform for cognitive, neuromuscular, and movement disorders. Synapticure operates a single, standardized clinical operation across all 50 states, including in‑home research capacity, and was selected as a CMS GUIDE provider in all 50 states. The company reports it can provide appointments within two weeks and partners with ACOs, health systems, and health plans to lower costs and improve quality of life. Synapticure plans to use new funding to expand partnerships with providers and payers, invest in its proprietary technology platform (including AI-enabled analytics and remote monitoring), fast-track clinical research and trial enrollment, and scale its national medical group. Leadership and founding includes caregiver-advocates Sandra Abrevaya and Brian Wallach. Synapticure is a Chicago-based teleneurology company that provides personalized care for people living with ALS and their families. The company is building a full-stack teleneurology platform that provides access and continuity of care, including personalized care plans developed through testing, data analytics, and consultations with ALS specialists. It is collaborating with ALS clinics across the country, including Massachusetts General Hospital and University of California San Francisco. Founded by Brian Wallach and Sandra Abrevaya, Synapticure's team, board, and advisory board include clinicians and industry leaders across neurology, genetics, and health tech. Synapticure launched with $6M in seed funding and will use the capital to rapidly scale its care platform to people living with ALS across the United States.